【摘要】 目的采用中药黄芪复方调节重症肌无力(myastheniagravis,MG)患者血清乙酰胆碱受体抗体(acetylcholinereceptorantibody,AChRAb)水平,以探讨其治疗MG的可能作用机制。方法应用酶联免疫吸附法(ELISA)检测74例MG患者治疗前后血清AChRAb水平,并采用许(氏)临床绝对和相对记分法观察病情严重程度和判定中药复方疗效。结果MG患者治疗前血清AChRAb水平(108±007)显著高于健康对照组(016±011)(P<001),治疗后MG患者血清AChRAb水平(072±006)明显下降(P<001)。结论具有补益脾肾作用的中药黄芪复方能下调MG患者血清AChRAb水平,从而纠正MG患者免疫失衡状态,临床绝对记分和相对记分对其疗效的判定有一定意义。更多还原

【Abstract】 Objective To observe the mechanism of Huangqi compound by regulating the acetylcholine receptor antibody (AChRAb) level in blood of myasthenia gravis (MG) patients. Methods Detect AChRAb level by enzyme-linked immunosorbent assay (ELISA) in MG blood, observe the severity of MG and estimate the effects of Huangqi compound by clinical scores. Results The level of AChRAb in MG blood before treatment (1.08±0.07) is higher than that of the healthy (0.16±0.11)(P<0.01), and it reduces after the treatment of Huangqi compound (0.72±0.06)(P<0.01). Conclusions Huangqi compound can reduce AChRAb level in blood and regulate immunological inbalance of MG patients; the method of absolute or relative clinical score is significant for estimating the effects of Huangqi compound.更多还原